Navigation Links
Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
Date:5/17/2012

CHICAGO, IL (May 16, 2012)For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule. However, in an effort to improve toxicity, standard MVAC has been essentially abandoned in favor of other regimens. All current standard neoadjuvant regimens require 12 weeks of chemotherapy.

Now, final results from a phase II clinical trial at Fox Chase Cancer Centerto be presented at the 2012 American Society of Clinical Oncology Annual Meeting on Saturday, June 2point to a treatment regimen that delivers benefits comparable to those of standard MVAC but without the same time requirement. Preliminary findings from the trial show that when MVAC is administered on an accelerated schedule (six weeks instead of 12), accelerated MVAC (AMVAC) patients experienced similar response rates and lower toxicity.

"Accelerated MVAC is an excellent option in terms of efficiency, quick time to surgery, tolerability, and complete response rate," says Elizabeth Plimack, M.D., a medical oncologist at Fox Chase. "It means less time off work for the patient, and less time elapses between their diagnosis and surgery. We hope that this regimen, which is well tolerated and can be given efficiently and quickly without sacrificing effectiveness, will help improve acceptance of neoadjuvant chemotherapy in the medical oncology and urology community."

Plimack and her colleagues recruited patients with muscle-invasive bladder cancer from Fox Chase and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. Patients underwent AMVAC every two weeks for six weeks and had a radical cystectomy within 8 weeks of the last chemotherapy.

Of the 33 patients who underwent all three rounds of AMVAC, for whom final data is available, 13 (39.1 percent) had a pathologic complete response at the time of surgery. Pathologic complete response, a common prognostic indicator for bladder cancer, indicates that the pathology evaluation of the resected bladder revealed no cancerous cells. The tumors of an additional three patients (9.1 percent) were downstaged during the pathology evaluation, suggesting that AMVAC had some effect in those patients as well. Final data will be presented at the meeting.

The AMVAC data suggest an accelerated course of chemotherapy before surgery confers comparable benefit as standard, 12-week MVACbut without the high toxicity associated with standard treatment.

The National Cancer Institute estimates that nearly 75,000 people will be diagnosed with bladder cancer in 2012, and nearly 15,000 will die from the disease. Patients who are diagnosed with bladder cancer that has spread into the muscle layer of the bladder wall have significantly lower survival rates than those patients whose tumors are confined to the inside lining of the organ. Existing treatment for invasive bladder cancer is unlikely to cure the disease, though it may prolong the time before the disease progresses or symptoms reappear.

"As medical oncologists, we are able to offer cancer-specific therapy to many of our bladder cancer patients, but unfortunately at this time there are few situations where chemotherapy helps achieve cure," says Plimack. "Neoadjuvant chemotherapy has been shown to provide incremental benefit in what I think is the most important endpoint, which is bladder cancer specific survival at five years. Most patients who are cancer free at five years do not experience a recurrence of their cancer. Our goal is to improve the chance of cure for patients going to cystectomy."

At Fox Chase, Plimack specializes in researching and treating patients with kidney, bladder, prostate and testicular cancers. She often recommends AMVAC to her own patients, and points out that the regimen is the preferred neoadjuvant, or pre-surgery, treatment at many academic centers in the United States and abroad.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Accelerated infant growth increases risk of future asthma symptoms in children
2. UCI-led study links prenatal exposure to stress with accelerated cell aging
3. Increased metabolic rate may lead to accelerated aging
4. Chronic stress of cancer causes accelerated telomere shortening
5. Experts call for accelerated national sodium reduction initiatives
6. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
7. PHNS Implements New Accelerated Claims Resolution Services With iSoftStone
8. Chemotherapys effect on overall survival seems to increase based on tumor size
9. Genetic predictor of breast cancer response to chemotherapy
10. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
11. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... ... November 11, 2019 , ... ... services to dental groups in the United States, today announced the grand opening ... Lodi, CA. , Patients will enjoy convenient hours, comfortable offices and full-service care ...
(Date:11/11/2019)... ... November 11, 2019 , ... American Family Care ... medicine, is expanding its long-term partnership with 919 Marketing , a national ... more than 200 locations across the country, American Family Care (AFC) is enlisting ...
(Date:11/11/2019)... ... November 11, 2019 , ... PracticeLink Live! Atlanta Physician Career Fair will take ... at 5:00 p.m. and continue until 8:00 p.m. A free, optional seminar for job-seeking ... at 6:30 p.m. , Both the career fair and seminar are open to residents ...
(Date:11/9/2019)... , ... November 08, 2019 , ... Mount Sinai Medical-Legal ... patients, unveiled two initiatives that provide free special education law and advocacy assistance to ... at Mount Sinai that also honored the work of contributions of Blaine (“Fin”) Fogg, ...
(Date:11/7/2019)... (PRWEB) , ... November 06, 2019 , ... An October ... obesity in the United States. According to the article, while no U.S. state had ... population that is over 20 percent obese. The article cites quite a few reasons ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... ... November 11, 2019 , ... Attorneys ... filed a statement before U.S. Bankruptcy Court Judge Robert Drain in White Plains, ... in America’s prescription opioid epidemic cannot be forgotten as a $12 billion settlement ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... the coordination and implementation of joint projects for the benefit of biomedical ... will empower biomedical professionals to leverage their roles in the research, development, ...
(Date:11/11/2019)... CLEARWATER, Fla. (PRWEB) , ... November 11, 2019 , ... On November 1st, Dr. Todd ... Day of Care for Veterans. Dr. Britten and his team are aware that dental ... “hit the ground running” in 2015 trying to deliver periodontal care to as many veterans ...
Breaking Medicine Technology: